Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Toombs

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Stem Cells (Dayton, Ohio)|September 30, 2000
The effect of MGDF on platelet function and thrombosis in animal modelsC F Toombs
Haemostasis|March 23, 2002
Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysisC F Toombs
Current Opinion in Pharmacology|November 21, 2001
New directions in thrombolytic therapyC F Toombs
Cardiovascular Research|October 1, 1993
ATP-dependent potassium channel openers and preconditioningC F Toombs, J Vinten-Johansen
Pharmacology|February 1, 1996
Reduction in infarct size by ischemic preconditioning persists in a chronic rat model of myocardial ischemia-reperfusion injuryF D Lott, P Guo, C F Toombs
Circulation|November 1, 1993
Ischemic preconditioning fails to limit infarct size in reserpinized rabbit myocardium. Implication of norepinephrine release in the preconditioning effectC F Toombs, A L Wiltse, R J Shebuski
Life Sciences|February 17, 1998
BIBP3226 inhibits neuropeptide Y and pancreatic polypeptide potentiated neurogenic vasoconstrictionV E Barrios, A G Nelson, C F Toombs
Pharmacology|August 1, 1994
Cardioprotection with U-89232 is not reversible with glibenclamide: evidence of a novel anti-ischemic agent derived from cromakalimC F Toombs, T L Moore, R J Shebuski
Cardiovascular Research|April 1, 1993
Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamideC F Toombs, T L Moore, R J Shebuski
Peptides|September 28, 1999
Evidence of a specific pancreatic polypeptide receptor in rat arterial smooth muscleV E Barrios, J Sun, J Douglass, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Stem Cells (Dayton, Ohio)|September 30, 2000
The effect of MGDF on platelet function and thrombosis in animal modelsC F Toombs
Haemostasis|March 23, 2002
Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysisC F Toombs
Current Opinion in Pharmacology|November 21, 2001
New directions in thrombolytic therapyC F Toombs
Cardiovascular Research|October 1, 1993
ATP-dependent potassium channel openers and preconditioningC F Toombs, J Vinten-Johansen
Pharmacology|February 1, 1996
Reduction in infarct size by ischemic preconditioning persists in a chronic rat model of myocardial ischemia-reperfusion injuryF D Lott, P Guo, C F Toombs
Circulation|November 1, 1993
Ischemic preconditioning fails to limit infarct size in reserpinized rabbit myocardium. Implication of norepinephrine release in the preconditioning effectC F Toombs, A L Wiltse, R J Shebuski
Life Sciences|February 17, 1998
BIBP3226 inhibits neuropeptide Y and pancreatic polypeptide potentiated neurogenic vasoconstrictionV E Barrios, A G Nelson, C F Toombs
Pharmacology|August 1, 1994
Cardioprotection with U-89232 is not reversible with glibenclamide: evidence of a novel anti-ischemic agent derived from cromakalimC F Toombs, T L Moore, R J Shebuski
Cardiovascular Research|April 1, 1993
Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamideC F Toombs, T L Moore, R J Shebuski
Peptides|September 28, 1999
Evidence of a specific pancreatic polypeptide receptor in rat arterial smooth muscleV E Barrios, J Sun, J Douglass, et al.
Pageof 3